Lung adenocarcinoma and squamous cases often carry driver alterations whose presence decides whether a targeted agent is appropriate. The 105-gene panel concentrates on the variants that actually steer first-line and later-line therapy for thoracic tumors. Rather than scanning the entire genome, this focused set keeps reporting fast and interpretation relevant to practicing oncologists.
Formalin-fixed tissue or a blood draw supplies the nucleic material that the laboratory sequences with validated chemistry. Hybridization capture enriches the 105 target regions so low-frequency clones stay detectable in heterogenous samples. Variant callers compare each tumor sequence against a reference genome and annotate clinically ranked findings. A molecular tumor board review step confirms that the listed alterations match the patient's disease stage.
Never-smokers with adenocarcinoma represent the subgroup most likely to harbor actionable kinase fusions screened here. Patients progressing after platinum chemotherapy can be re-profiled to surface newly emerged resistance mutations. Early-stage operable cases may be tested to support adjuvant targeted therapy discussions.
Turnaround averages seven working days from receipt of an acceptable specimen at the lab. Reports separate sensitizing and resistance calls so the clinician sees therapy direction at a glance. Each finding carries the evidence tier that justifies its inclusion in the recommendation. Pathology review confirms tumor content before extraction so the final call reflects the lesion.
Residual extracted DNA is stored under controlled conditions for thirty days to allow confirmatory testing. International orders ship in validated cold packaging that preserves nucleic acid integrity. Volume programs for clinics include secure portal access and batch result export. Monthly distributor calls are supported through the portal so reordering stays frictionless for clinics.
Q: Which lung cancer patients should consider the 105-gene panel? A: Adenocarcinoma and squamous cases being evaluated for targeted options, especially never-smokers, gain the most from this focused profile.
Q: Is tissue or plasma acceptable for this panel? A: Both formalin-fixed tissue and blood-derived cell-free DNA are accepted depending on what the clinician can obtain.
Q: How long before the report reaches the clinic? A: Results typically post within seven working days after the laboratory accepts a quality-passed specimen.
Q: Does the panel cover hereditary risk genes? A: A limited set of hereditary markers is included, and a separate germline review can be requested when family history is suggestive.
Lung adenocarcinoma and squamous cases often carry driver alterations whose presence decides whether a targeted agent is appropriate. The 105-gene panel concentrates on the variants that actually steer first-line and later-line therapy for thoracic tumors. Rather than scanning the entire genome, this focused set keeps reporting fast and interpretation relevant to practicing oncologists.
Formalin-fixed tissue or a blood draw supplies the nucleic material that the laboratory sequences with validated chemistry. Hybridization capture enriches the 105 target regions so low-frequency clones stay detectable in heterogenous samples. Variant callers compare each tumor sequence against a reference genome and annotate clinically ranked findings. A molecular tumor board review step confirms that the listed alterations match the patient's disease stage.
Never-smokers with adenocarcinoma represent the subgroup most likely to harbor actionable kinase fusions screened here. Patients progressing after platinum chemotherapy can be re-profiled to surface newly emerged resistance mutations. Early-stage operable cases may be tested to support adjuvant targeted therapy discussions.
Turnaround averages seven working days from receipt of an acceptable specimen at the lab. Reports separate sensitizing and resistance calls so the clinician sees therapy direction at a glance. Each finding carries the evidence tier that justifies its inclusion in the recommendation. Pathology review confirms tumor content before extraction so the final call reflects the lesion.
Residual extracted DNA is stored under controlled conditions for thirty days to allow confirmatory testing. International orders ship in validated cold packaging that preserves nucleic acid integrity. Volume programs for clinics include secure portal access and batch result export. Monthly distributor calls are supported through the portal so reordering stays frictionless for clinics.
Q: Which lung cancer patients should consider the 105-gene panel? A: Adenocarcinoma and squamous cases being evaluated for targeted options, especially never-smokers, gain the most from this focused profile.
Q: Is tissue or plasma acceptable for this panel? A: Both formalin-fixed tissue and blood-derived cell-free DNA are accepted depending on what the clinician can obtain.
Q: How long before the report reaches the clinic? A: Results typically post within seven working days after the laboratory accepts a quality-passed specimen.
Q: Does the panel cover hereditary risk genes? A: A limited set of hereditary markers is included, and a separate germline review can be requested when family history is suggestive.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
